Vertex Pharmaceuticals Incorporated · Healthcare
Survives a correction-sized 3-point cut to analyst growth.
At a 32.0% margin the price requires 5.0% 3y revenue CAGR against 11.4% consensus, a cushion of +4.7pt versus a 0pt correction cut. Cushion clears the cut, so the price survives the correction on consensus estimates. Unaffected.
Breaks if: pipeline diversification (povetacicept) stalls. We re-check this against analyst estimates every evening.
10 years, at a 32% margin (analysts' margin, cut for cash conversion)
+7.8%/yr over 10 years once faded to terminal growth
points off 3-year analyst growth
14 published targets, set before the drop
Does the profit analysts build their margin on actually arrive as cash? Measured over the last 3 annual statements filed before this test. After stock-based pay, 67% of reported profit arrived as operating cash, so the test cuts the analysts' 36% margin to 24%. That leaves a cushion of −1pt instead of +7pt, and the smaller of the two decides the group.
How much of reported profit arrived as operating cash. Below 0.8× is a red flag.
Profit not backed by cash, as a share of assets, latest year. Above 10% is a red flag.
Staff paid in shares instead of cash, which flatters margins. Above 10% is a red flag.
Dilution of each share's claim on the business. Above 3% a year is a red flag.
Non-operating gains in the latest year. Above 25% is a red flag.
After capex. Shown for context: heavy investment is not bad earnings, so it is never solved under.
From the priced-in reconstruction of Sep 13, 2026. Its figures use that day's price and free-cash-flow margin, so they can differ from the stress test above.
The price at the price sits at the 21st percentile of published models, leaning bearish against the analyst set by declining to pay for the pipeline expansion upside that the majority of targets require.
Whether the combined endocrinology and renal pipeline can generate the $5+ billion in peak sales necessary to justify the 14.7% revenue CAGR the price requires, and the wired data cannot settle this because prescription volumes for unreleased drugs are not yet measurable.
What the price refuses to pay for, and the full reconstruction, on the VRTX quote page →A stress test of whether this narrative is still paid for by analyst forecasts, not a forecast that the stock will rise. The price-implied growth on its own has not predicted returns in our testing, and this list (sealed Nov 21, 2026) has not been graded yet. Cut sizes are assumptions. Not investment advice. Back to all names